Olema Oncology, Inc. OLMA
7.36 USD -0.20 (-2.65%)
Regular-session close
7.57 +0.21 +2.85%
Pre-market · Nov 17, 5:18 AM ET
7.08 Day range 7.73
6.24 52-week range 36.26
- YTD
- -70.56%
- 1 year
- -13.62%
News
globenewswire.com Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (“Olema,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization…
seekingalpha.com Olema Pharmaceuticals, Inc. (OLMA) Presents at Stifel 2026 Healthcare Conference 2026 Transcript Olema Pharmaceuticals, Inc. ( OLMA ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 10:40 AM EST Company Participants Sean Bohen - President, CEO & Director Conference Call Participants…
globenewswire.com Olema Oncology Announces Corporate Name Change SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company…
defenseworld.net Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Consensus Target Price of $40.60 Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the…benzinga.com Olema Pharmaceuticals Q3 EPS $(0.73) Misses $(0.63) Estimate Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.63) by 17.74 percent. This is a 48.98 percent decrease over…
globenewswire.com Olema Oncology Reports Third Quarter 2026 Financial and Operating Results SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,…
